NCT02829723 - A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors | Biotech Hunter

Enrollment

192

Participants

Timeline

Start Date

October 21, 2016

Primary Completion Date

December 1, 2022

Study Completion Date

December 1, 2022

Conditions

Advanced Solid Tumors

Interventions

DRUG

BLZ945

"BLZ945 administered orally as a capsule. Up to five alternative dosing schedules were evaluated: once per day (QD) 7 days on/7 days off (i.e., administer BLZ945 for 7 days and suspend for 7 days), QD 4 days on/10 days off, twice per day (BID) 4 days on/10 days off, once weekly (Q1W) QD and Q1W BID.~Each cycle consisted of 28 days."

DRUG

PDR001

PDR001 400 mg administered via intravenous (i.v.) infusion every 4 weeks (Q4W)

Trial Locations (14)

8091

Novartis Investigative Site, Zurich

10002

Novartis Investigative Site, Taipei

20089

Novartis Investigative Site, Rozzano

28041

Novartis Investigative Site, Madrid

37203

Sarah Cannon Research Institute Sarah Cannon Research, Nashville

77030

UT M.D Anderson Cancer Center, Houston

78229

Mays Cancer Ctr Uthsa Mdacc, San Antonio

168583

Novartis Investigative Site, Singapore

6423906

Novartis Investigative Site, Tel Aviv

02215

Dana Farber Cancer Institute Dana Farber Cancer Institute, Boston

466 8560

Novartis Investigative Site, Nagoya

135 8550

Novartis Investigative Site, Koto Ku

08035

Novartis Investigative Site, Barcelona

08907

Novartis Investigative Site, L'Hospitalet de Llobregat